Synthetic Cannabinoid Receptor Agonist (SCRA) Screen

General Information

Synthetic Cannabinoid Receptor Agonists (SCRAs), also known as synthetic cannabinoids or colloquially as spice, mamba or K2 are a group of drugs with some structural and functional similarity to the active ingredients in cannabis (e.g. THC and CBD). These synthetic cannabinoids are typically sprayed onto dried plant matter so they can be smoked or sold as liquids to be vaporised or inhaled in e-cigarettes or similar.

Effects of synthetic cannabinoid use are similar, but more pronounced, than cannabis with effects such as relaxation, euphoria, lethargy, confusion, anxiety, fear hallucinations, paranoia, tachycardia, nausea and vomiting reported.

Symptoms of synthetic cannabinoid overdose include cardiovascular toxicity (including sudden death), central nervous system and respiratory depression, seizures, convulsions, hyperemesis, psychosis and aggressive behaviour. These compounds are extensively used in certain populations (e.g. prisons, homeless)  and due to their physiochemical properties a specific screening method has been developed.

At UHB, SCRAs are screened for using solid phase extraction followed by high resolution mass spectrometry (LC-HRMS).  The following synthetic cannabinoids and their metabolites are included: MDMB-4en-PINACA, 5F-MDMB-PINACA (5F-ADB), ADB-BUTINACA, 5F-MDMB-PICA, 4F-MDMB-BUTINACA (4F-MDMB-BINACA), MDMB-FUBINACA, and AB-MDMSBA.

The scope of the analysis is being constantly updated to reflect changing trends in synthetic cannabinoid use amongst the population.

Should you have any questions regarding a Synthetic Cannabinoid Receptor Agonist (SCRA) Screen - please contact the laboratory on 0121 424 3707.